ArticleFunctional & integrative genomics2026
PSMG3 enhances the proliferation and metastasis of hepatocellular carcinoma via inhibiting HDAC6.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is one of the most frequent cancers globally, characterized by significant metastasis and poor prognosis. The proteasome is critical to the pathogenesis of HCC; however, its mechanisms are not fully elucidated. Here, we explored the role of Proteasome Assembly Chaperone 3 (PSMG3) during HCC progression. In this research, both a subcutaneous tumorigenesis model and a lung metastasis model were established in nude mice to investigate the impact of PSMG3 on the proliferation and metastasis of HCC cells. Chromatin immunoprecipitation (ChIP) assays and dual-luciferase reporter assays were performed to determine the regulatory role of the transcription factor CEBPA on PSMG3. Moreover, the RNA sequencing and label-free quantitative proteomics were employed to clarify the mechanisms through which PSMG3 enhances HCC progression. The results indicated that PSMG3 promoted the proliferation and metastasis of HCC. Mechanistically, CEBPA bound to the promoter of PSMG3 and enhanced its transcription. PSMG3 exerted its pro-tumorigenic effects on HCC by modulating the expression of Histone deacetylase 6 (HDAC6). In summary, we show that the CEBPA/PSMG3/HDAC6 axis promotes HCC progression and that PSMG3 might represent a promising therapeutic target in HCC.
Indexed as
Identifiers
41999493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.